Opill, the first daily oral contraceptive approved for sale without a prescription in the United States, became available on store and pharmacy shelves in 2024 after FDA approval in July 2023 — a change that removed the prescription barrier for a progestin-only pill for the first time in U.S. history. The pill's list price was set at about $20 for a one-month pack, or roughly $90 for three months, per the manufacturer's announced pricing. The qualification that matters most now: insurance does not automatically cover OTC purchases, so the out-of-pocket price is what most buyers pay.
One Women's Health publishes information, not medical advice. Contraception choices belong with a clinician or pharmacist, and this article covers availability and policy, not what any individual should take.
What changed with the OTC switch?
Access, not the product. Opill (norgestrel 0.075 mg) had been prescription-only since its original approval decades earlier; the 2023 FDA switch was based on manufacturer studies showing consumers could use it safely by following the label, per the FDA's approval announcement. Progestin-only pills suit many people but carry label warnings — including prior breast cancer — that a pharmacist or clinician can help apply to an individual history, which the label itself directs readers to check.
How effective is it in real use?
About 98% effective with typical use, per the FDA's consumer information — better than condoms in typical use, less forgiving than prescription pills taken at a consistent daily time, because progestin-only pills have a narrower window for late doses. The context other coverage skipped: effectiveness numbers for OTC labels assume label-following, and the FDA's approval studies specifically tested whether people could follow the label without a clinician — a real finding, and the basis of the switch.
What does it change for readers?
Two things, one settled and one moving. Settled: no appointment, no prescription, and pharmacy counters in all 50 states can sell it, with some state Medicaid programs and a federal coverage program absorbing cost for eligible users. Moving: insurance equivalence. The Affordable Care Act's contraception coverage guarantee applies to prescribed methods, and coverage of OTC purchases without a prescription depends on state law and plan design — a patchwork tracked by policy groups through 2025, with several states enacting OTC coverage mandates and others not. The practical consequence: check the plan, not the shelf.
What the record establishes is a genuine access expansion with an out-of-pocket asterisk. What remains unresolved is whether federal coverage rules catch up to the OTC status — pending regulation, not settled law, and no source can predict its outcome.
For more context, read Self-collected HPV tests: what the guidelines actually say.
For more context, read sleep quality and women's health.